Myriad Genetics, Inc.
NASDAQTotal Valuation
Myriad Genetics, Inc. carries a market capitalization of 532.77M, placing it among publicly traded companies globally. Its enterprise value stands at 545.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 532.77M |
| Enterprise Value | 545.88M |
Share Statistics
Myriad Genetics, Inc. currently has 95.60M shares outstanding.
| Shares Outstanding | 95.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 0.87 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | 33.45 |
| P/OCF Ratio | 33.45 |
Enterprise Valuation
| EV / Sales | 0.89 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 19.26 |
Financial Position
Myriad Genetics, Inc. maintains a current ratio of 9.43, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 245.91, indicating elevated leverage, while an interest coverage ratio of -1.13 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.43 |
| Quick Ratio | 7.39 |
| Debt / Equity | 245.91 |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.13 |
Financial Efficiency
| Return on Equity (ROE) | -35.76 |
| Return on Assets (ROA) | -20.49 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 13.08 |
Taxes
| Income Tax | 200,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Myriad Genetics, Inc.'s stock has declined approximately -30.8933% over the past 52 weeks. The 50-day moving average sits at 3.73, while the 200-day moving average is 4.62.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.8933% |
| 50-Day Moving Average | 3.73 |
| 200-Day Moving Average | 4.62 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Myriad Genetics, Inc. generated 615.90M in revenue and converted that into -69.40M in net income, yielding earnings per share of -0.74. EBITDA reached -13.90M, while operating income came in at -51.60M.
| Revenue | 615.90M |
| Gross Profit | 428.20M |
| Operating Income | -51.60M |
| Pretax Income | -69.20M |
| Net Income | -69.40M |
| EBITDA | -13.90M |
| EBIT | -51.60M |
| Earnings Per Share (EPS) | -0.74 |
Cash Flow
Myriad Genetics, Inc. produced 16.00M in operating cash flow over the past twelve months.
| Operating Cash Flow | 16.00M |
| Capital Expenditures | N/A |
| Free Cash Flow | 16.00M |
| FCF Per Share | 0.17 |
Margins
Myriad Genetics, Inc. operates with a gross margin of 69.52, reflecting its pricing power and cost economics. The operating margin of -8.38 and net profit margin of -11.27 provide insight into operational efficiency.
| Gross Margin | 69.52 |
| Operating Margin | -8.38 |
| Pretax Margin | -11.24 |
| Profit Margin | -11.27 |
| EBITDA Margin | -2.26 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -8.24 |
| FCF Yield | 2.99 |
Stock Splits
Myriad Genetics, Inc.'s most recent stock split took place on March 26, 2009 with a 1:2 split ratio.
| Last Split Date | 3/26/2009 |
| Split Ratio | 1:2 |
Scores
Myriad Genetics, Inc. posts an Altman Z-Score of -2.87, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.87 |